期刊文献+
共找到828篇文章
< 1 2 42 >
每页显示 20 50 100
DRUG THERAPY OF PAROXYSMAL ATRIAL FIBRILLATION IN THE ELDERLY OVER 75 YEARS OLD
1
作者 De-you Chen Jian Cao Bing-po Zhu 《Chinese Medical Sciences Journal》 CAS CSCD 2006年第1期16-19,共4页
Objective To investigate the effectiveness and safety of various agents on paroxysmal atrial fibrillation in the elderly over 75 years old.Methods Totally 264 in-patients (75-91 years old, 185 males and 79 females) wi... Objective To investigate the effectiveness and safety of various agents on paroxysmal atrial fibrillation in the elderly over 75 years old.Methods Totally 264 in-patients (75-91 years old, 185 males and 79 females) with atrial fibrillation history of less than 7 days were enrolled in this study.A total of 611 atrial fibrillation episodes were recorded, but 130 episodes (22.3%) of atrial fibrillation were auto-converted to sinus rhythm.The rest 481 episodes of atrial fibrillation were divided into six groups based on the drug used.Results The cardioversion ratio of atrial fibrillation were 9.5%, 46.9%, 71.7%, 55.9%, 32.7%, and 73.6% in control, cedilanid, amiodarone, propafenone, verapamil, and quinidine groups, respectively.Ventricular rate control were 5.4%, 83.6%, 84.9%, 77.9%, 78.8%, and 11.3% in those groups, respectively.The total effective rates of amiodarone and cedilanid groups were the highest. When the ventricular rate was controlled to below 90 bpm, the patients would almost complain of no discomfort. No severe side-effect was observed in each group.Conclusion Amiodarone and cedilanid may be the proper drugs for the treatment of paroxysmal atrial fibrillation in the elderly.The above antiarrhythmics in each therapeutic group were relatively safe and effective. 展开更多
关键词 atrial fibrillation drug therapy aged
下载PDF
Long-term stroke rates after catheter ablation or antiarrhythmic drug therapy for atrial fibrillation: a meta-analysis of randomized trials
2
作者 Ya-Ru ZHENG Zhi-Yun CHEN +1 位作者 Li-Fang YE Li-Hong WANG 《Journal of Geriatric Cardiology》 SCIE CAS CSCD 2015年第5期507-514,共8页
Background Atrial fibrillation (AF) is an independent risk factor for ischemic stroke and is associated with increased risk of death. Randomized studies suggest improved quality of life for patients with AF after su... Background Atrial fibrillation (AF) is an independent risk factor for ischemic stroke and is associated with increased risk of death. Randomized studies suggest improved quality of life for patients with AF after successful catheter ablation compared to antiarrhythmic drug therapy. The value of ablation in long-term risk of ischemic stroke, however, has not been assessed. We conducted a meta-analysis to determine whether AF ablation reduces the long-term risk of stroke compared to antiarrhythmic drug therapy in randomized controlled trials. Methods & Results PubMed and the Cochrane Central Register were searched for randomized trials from January 1990 to December 2014 comparing AF catheter ablation to drug therapy. The results are reported as risk differences (RDs) and 95% CI. Thirteen trials were analyzed with 1097 patients treated by catheter ablation and 855 patients received antiarrhythmic drug therapy. Overall, seven patients (0.64%) in the catheter ablation group had ischemic stroke or transient ischemic attacks vs. two patients (0.23%) in the drug therapy group. No difference was shown in the rate of stroke or transient ischemic attack between ablation and drug therapy (RD: 0.003, 95% CI: -0.006 to 0.012, P = 0.470), and no evidence of heterogeneity was observed (I^2 = 0, P = 0.981). No potential publication bias was found. There was also no difference in mortality between the two groups (RD: -0.004, 95% CI: -0.014 to 0.006, P = 0.472). Conclusions This meta-analysis of randomized controlled trials showed similar rates of ischemic stroke or transient ischemic attack and death in AF patients undergoing catheter ablation compared to drug therapy. A larger prospective randomized trial to confirm this finding is warranted. 展开更多
关键词 atrial fibrillation Antiarrhythmic drug Catheter ablation DEATH STROKE
下载PDF
Atrial fibrillation and coronary artery disease:An integrative review focusing on therapeutic implications of this relationship 被引量:4
3
作者 Akash Batta Juniali Hatwal +2 位作者 Akshey Batta Samman Verma Yash Paul Sharma 《World Journal of Cardiology》 2023年第5期229-243,共15页
The incidence of both atrial fibrillation(AF)and coronary artery disease(CAD)increases with advancing age.They share common risk factors and very often coexist.Evidence points to an intricate relationship between atri... The incidence of both atrial fibrillation(AF)and coronary artery disease(CAD)increases with advancing age.They share common risk factors and very often coexist.Evidence points to an intricate relationship between atrial tissue excitability and neuronal remodeling with ischemia at the microcirculatory level.In this review,we delineated this complex relationship,identified a common theme between the two,and discussed how the knowledge of this relationship translates into a positive and meaningful impact in patient management.Recent research indicates a high prevalence of CAD among AF patients undergoing coronary angiography.Further,the incidence of AF is much higher in those suffering from CAD compared to age-matched adults without CAD underlying this reciprocal relationship.CAD adversely affects AF by promoting progression via re-entry and increasing excitability of atrial tissue as a result of ischemia and electrical inhomogeneity.AF in turn accelerates atherosclerosis via endothelial dysfunctional and inflammation and together with enhanced thrombogenicity and hypercoagulability contribute to micro and macrothrombi throughout cardiovascular system.In a nutshell,the two form a vicious cycle wherein one disease promotes the other.Most AF recommendations focuses on rate/rhythm control and prevention of thromboembolism.Very few studies have discussed the importance of unmasking coexistent CAD and how the treatment of underlying ischemia will impact the burden of AF in these patients.Inflammation and endothelial dysfunction remain central to both disease processes and form a handsome therapeutic target in the management of the two diseases.The relationship between AF and CAD is complex and much more than mere coincidence.The two diseases share common risk factor and pathophysiology.Hence,it is impractical to treat them in isolation.Accordingly,we share the implications of managing underlying ischemia and inflammation to positively impact and improve quality of life among AF patients. 展开更多
关键词 atrial fibrillation Coronary artery disease Antithrombotic therapy ISCHEMIA Early rhythm control Endothelial dysfunction
下载PDF
Is dual therapy the correct strategy in frail elderly patients with atrial fibrillation and acute coronary syndrome? 被引量:7
4
作者 Alessio Menditto Roberto Antonicelli 《Journal of Geriatric Cardiology》 SCIE CAS CSCD 2020年第1期51-57,共7页
Atrial fibrillation(AF)is a very common arrhythmia in clinical practice.Its incidence and prevalence are age-related and are growing in the last years.Age is a risk factor also for coronary artery disease(CAD),and wit... Atrial fibrillation(AF)is a very common arrhythmia in clinical practice.Its incidence and prevalence are age-related and are growing in the last years.Age is a risk factor also for coronary artery disease(CAD),and with the evolution of preventive care,the first event(acute coronary syndrome(ACS)or percutaneous coronary intervention(PCI))takes place at a later age.If elderly patients with AF and CAD undergo ACS or PCI,they have indication to assume triple therapy.Triple therapy(oral anticoagulation(OAC)plus dual antiplatelet therapy(DAPT))exposes patients to high bleeding risk.In the last 10 years,several clinical trials have tested dual therapy(OAC plus single antiplatelet therapy)in AF patients who undergo ACS or elective PCI.WOEST trial has tested warfarin+clopidogrel against triple therapy.PIONEER AF-PCI trial has tested low-dose rivaroxaban+P2Y12 inhibitor or very low-dose rivaroxaban+DAPT against standard triple therapy with warfarin.RE-DUAL PCI trial has tested two doses of dabigatran+P2Y12 inhibitor against standard triple therapy with Warfarin.AUGUSTUS trial has tested apixaban against warfarin both in dual therapy with P2Y12 inhibitor and in triple therapy with a P2Y12 inhibitor and aspirin.ENTRUST-AF PCI,last published study,has tested edoxaban+P2Y12 inhibitor against triple therapy.All these trials show dual therapy reduces significantly bleeding risk than triple therapy.In this paper,we analyze these clinical trials to understand if dual therapy results can be applied to elderly patients and what is probably the better approach in elderly AF patients undergo to ACS or PCI. 展开更多
关键词 Acute coronary syndrome atrial fibrillation Dual therapy Oral anticoagulation The elderly
下载PDF
The trend of change in catheter ablation versus antiarrhythmic drugs for the management of atrial fibrillation over time: a meta-analysis and meta-regression 被引量:1
5
作者 Wei LIU Qiang WU +1 位作者 Xiao-Jie YANG Jing Huang 《Journal of Geriatric Cardiology》 SCIE CAS CSCD 2018年第6期441-450,共10页
Objective To evaluate the trend of change in the efficacy and safety of catheter ablation compared with antiarrhythmic drug therapy (ADT) for rhythm control in patients with atrial fibrillation (AF) over time. Met... Objective To evaluate the trend of change in the efficacy and safety of catheter ablation compared with antiarrhythmic drug therapy (ADT) for rhythm control in patients with atrial fibrillation (AF) over time. Methods The online databases PubMed and EMBASE were searched for relevant studies. STATA software (version 12.0) was used to perform the meta-analysis and meta-regression. Results Fifteen randomized controlled trials including 2249 patients with AF were identified. The pooled results showed that catheter ablation was associated with a 52% reduction in the risk of AF recurrence compared with ADT [risk ratio (RR) = 0.48, 95% confidence interval (CI): 0.40-0.57, I2 = 70.7%). Subgroup analyses showed that catheter ablation exhibited less efficacy in studies after 2011 compared to studies before 2011 (RR = 0.61, 95% CI: 0.54-0.68, I2 = 9.3% and RR = 0.34, 95% CI: 0.24-0.47, I2 = 69.9%, respectively), and the safety outcome showed a 1.08-fold higher incidence of adverse events (14.2% vs. 7.3%; RR = 1.08, 95% CI: 1.04-1.13) in studies after 2011. Conclusions Catheter ablation appears to be superior to ADT for rhythm control. However, less efficacy and a higher rate of adverse events were observed in studies after 2011 compared to studies before 2011. 展开更多
关键词 Antiarrhythmic drug therapy atrial fibrillation Catheter ablation RHYTHM
下载PDF
Contemporary therapy of atrial fibrillation
6
作者 Xing Sheng Yang Jing Ping Sun Cheuk Man Yu 《World Journal of Cardiovascular Diseases》 2012年第3期111-117,共7页
Atrial fibrillation (AF) is estimated that by 2010, approximately 2.6 million people will be affected in USA;by 2050, that number may increase to 10 million patients. Generally, rate control alone is reasonable in som... Atrial fibrillation (AF) is estimated that by 2010, approximately 2.6 million people will be affected in USA;by 2050, that number may increase to 10 million patients. Generally, rate control alone is reasonable in some AF patients, especially asymptomatic patients. Restoration and maintenance of sinus rhythm (SR) may be achieved by means of cardioversion, drugs or/ and catheter ablation. Pharmacological therapy can be useful to maintain SR and prevent tachycardia-induced cardiomyopathy. All patients with AF regardless of whether a rhythm or rate control strategy recommend anticoagulant, antiplatelet or both combined therapy for prevention of thromboembolism, except those with lone AF or contraindications. Drug selection should be based upon the absolute risk of stroke, bleeding, the relative risk and benefit for a given patient. Biventricular pacing may overcome many of the adverse hemodynamic effects associated with RV pacing alone. A target individual ectopic foci ablation within the pulmonary vein (PV) has evolved to circumferential electrical isolation of the entire PV musculature. Cavotricuspid isthmus should be considered as first-line therapy for patients with typical atrial flutter. Completely non-fluoroscopic ablation guided by Real-Time Magnetic Resonance Imaging (RTMRI) using a steerable and non-ferromagnetic catheter is a promising novel technology in interventional electrophysiology. 展开更多
关键词 atrial fibrillation ANTIARRHYTHMIC drug ANTICOAGULANT therapy ANTIPLATELET therapy CARDIOVERSION Catheter Ablation
下载PDF
Atrial fibrillation in the elderly 被引量:9
7
作者 Pablo Díez-Villanueva Fernando Alfonso 《Journal of Geriatric Cardiology》 SCIE CAS CSCD 2019年第1期49-53,共5页
Atrial fibrillation(AF)is the most common arrhythmia in elderly population,with age being one of the most important factors involved in its pathogenesis.Conduction disturbances may be present on the surface electrocar... Atrial fibrillation(AF)is the most common arrhythmia in elderly population,with age being one of the most important factors involved in its pathogenesis.Conduction disturbances may be present on the surface electrocardiogram before AF onset in some patients.Once this arrhythmia is diagnosed,antithrombotic therapy is mandatory in most cases,as this is the only treatment that has demonstrated to improve survival.Age increases both the risk of thromboembolic and bleeding complications,while benefits from anticoagulant therapy outweigh that from bleeding in most scenarios,also in very elderly patients.However,elderly patients with AF are often undertreated.Non-vitamin K antagonist oral anticoagulants have emerged as an alternative to vitamin K antagonists,with significant less adverse events and better profile in terms of efficacy and safety.Other conditions related to age should be carefully evaluated in these patients(including frailty,comorbidity and polypharmacy)to ensure an individualized clinical and therapeutic approach. 展开更多
关键词 atrial fibrillation ANTITHROMBOTIC therapy FRAILTY Non-vitamin K ANTAGONIST oral ANTICOAGULANTS The elderly
下载PDF
Clinical characteristics and one year outcomes in Chinese atrial fibrillation patients with stable coronary artery disease: a population-based study 被引量:3
8
作者 Ying BAI Jun ZHU +6 位作者 Yan-Min YANG Yan LIANG Hui-Qiong TAN Juan WANG Bi HUANG Han ZHANG Xing-Hui SHAO 《Journal of Geriatric Cardiology》 SCIE CAS CSCD 2016年第8期665-671,共7页
Background Atrial fibrillation (AF) and coronary artery disease (CAD) often coexist, however, the clinical characteristics and the impact of stable CAD on the outcomes in Chinese patients with AF has not been well... Background Atrial fibrillation (AF) and coronary artery disease (CAD) often coexist, however, the clinical characteristics and the impact of stable CAD on the outcomes in Chinese patients with AF has not been well understood. Methods Consecutive AF patients in 20 hospitals in China from November 2008 to October 2011 were enrolled. The primary endpoints included 1-year all-cause mortality, stroke, non-central nervous system (non-CNS) embolism, and major bleeding. Results A total of 1947 AF patients were analyzed, of whom 40.5% had stable CAD. The mean CHADS2 scores in CAD patients were significantly higher than that of non-CAD patients (2.4 - 1.4 vs. 1.4 - 1.2, P 〈 0.001). During follow-up period, warfarin use is low in both groups, with relatively higher proportion in non-CAD patients compared with CAD patients (22.3% vs. 10.7%, P 〈 0.001). Compared with non-CAD patients, CAD patients had higher one-year all-cause mortality (16.8% vs. 12.9%, P = 0.017) and incidence of stroke (9.0% vs. 6.4%, P = 0.030), while the non-CNS embolism and major bleeding rates were comparable between the two groups. After multivariate adjustment, stable CAD was independently associated with increased risk of 1-year all-cause mortality (HR = 1.35, 95% CI: 1.01-1 .80, P = 0.040), but not associated with stroke (HR = 1.07, 95% CI: 0.72-1.58, P = 0.736). Conclusions Stable CAD was prevalent in Chinese AF patients and was independently associated with increased risk of 1-year all-cause mortality. Chinese AF patients with stable CAD received inadequate antithrombotic therapy and this grim status of antithrombotic therapy needed to be improved urgently. 展开更多
关键词 Antithrombotic therapy atrial fibrillation CHADS2 score Stable coronary artery disease
下载PDF
Omega 3 and atrial fibrillation:Where are we?
9
作者 Annamaria Martino Laura Pezzi +3 位作者 Roberta Magnano Elisa Salustri Maria Penco Leonardo Calo' 《World Journal of Cardiology》 CAS 2016年第2期114-119,共6页
Anti-arrhythmic properties of n-3 polyunsaturated fatty acids, at least in part mediated by anti-oxidant, anti-inflammatory and anti-fibrotic power, have been widely proved. Effect of fish oil on atrial fibrillation, ... Anti-arrhythmic properties of n-3 polyunsaturated fatty acids, at least in part mediated by anti-oxidant, anti-inflammatory and anti-fibrotic power, have been widely proved. Effect of fish oil on atrial fibrillation, both in primary and in secondary prevention and after cardiac surgery, are controversial, mostly due to lack of homogeneity between studies but also due to individual variability in response to fatty acids administration. Inclusion of measurement of incorporation of fish oil into cell membranes, appears to be essential in future studies, to assess their antiarrhythmic effect. 展开更多
关键词 N-3 polyunsaturated FATTY ACIDS atrial fibrillation UPSTREAM therapy Omega-3 index Cardiac surgery
下载PDF
Atrial fibrillation and concomitant left subclavian, axillary and brachial artery embolism after fiberoptic bronchoscopy: A case report
10
作者 Cui-Lin Yang Ran Zhou +4 位作者 Zhi-Xian Jin Min Chen Bao-Li Zi Ping Li Kai-Hua Zhou 《World Journal of Clinical Cases》 SCIE 2021年第33期10233-10237,共5页
BACKGROUND Fiberoptic bronchoscopy has been widely used in the diagnosis and treatment of respiratory diseases.Numerous major and minor complications have been reported following this procedure.The incidence of major ... BACKGROUND Fiberoptic bronchoscopy has been widely used in the diagnosis and treatment of respiratory diseases.Numerous major and minor complications have been reported following this procedure.The incidence of major postoperative complications is approximately 0.5%and includes respiratory depression,pneumothorax,pulmonary edema,pneumonia,airway obstruction and cardiorespiratory arrest.Minor complications include vasovagal reactions,cardiac arrhythmias,hemorrhage,pneumothorax,aphonia,nausea,vomiting and fever.However,to our knowledge,a case of atrial fibrillation(AF)concomitant with fatal arterial embolism in the upper extremities following diagnostic bronchoscopy has never been reported.CASE SUMMARY A 70-year-old female patient presented with a history of rheumatic heart disease beginning at 10 years of age and an approximately 10-year history of hypertension.The patient was transferred from the cardiology department to the respiratory department due to recurrent coughing,pneumonia,and fever.She underwent fiberoptic bronchoscopy in the respiratory department.Approximately 2 h after completion of bronchoscopy,she complained of left arm numbness and weakness.Physical examination detected cyanosis of the left upper extremity,grade III weakened limb muscle strength,and undetectable left brachial artery pulsation.Auscultation indicated AF.B-mode ultrasound examination of the blood vessels showed hyperechoic material in the left subclavian,axillary and brachial arteries,and parallel veins.As our hospital has no vascular surgery capability,the patient was transferred to a specialized hospital for emergency thrombectomy that day.A tracking investigation found that the patient’s conditions improved after successful thrombectomy.CONCLUSION Thromboembolism following bronchoscopy is rare,and only a few cases of cerebral air embolism after bronchoscopy have been reported. 展开更多
关键词 Fiberoptic bronchoscopy Complications atrial fibrillation THROMBOEMBOLISM Anticoagulant therapy Case report
下载PDF
经皮左心耳封堵术的争议与探索
11
作者 杨婧 尤玲 +4 位作者 张艳 张光明 耿雪 邢航航 谢瑞芹 《中国循环杂志》 CSCD 北大核心 2024年第8期828-832,共5页
经皮左心耳封堵术(LAAO)已成为不能耐受口服抗凝药的非瓣膜性心房颤动患者脑卒中预防的一种替代治疗策略。多项研究证实,LAAO预防血栓栓塞事件具有良好的安全性及有效性。随着国内外专家对LAAO逐渐认可,该技术在心房颤动患者脑卒中预防... 经皮左心耳封堵术(LAAO)已成为不能耐受口服抗凝药的非瓣膜性心房颤动患者脑卒中预防的一种替代治疗策略。多项研究证实,LAAO预防血栓栓塞事件具有良好的安全性及有效性。随着国内外专家对LAAO逐渐认可,该技术在心房颤动患者脑卒中预防方面得到了迅速发展,但仍有许多问题值得深入探究。本文从LAAO对左心房结构和功能的影响、最佳的LAAO策略以及LAAO术后最佳的抗栓治疗等方面进行综述。 展开更多
关键词 心房颤动 左心耳封堵术 左心房功能 封堵策略 抗栓治疗
下载PDF
共病及衰弱对高龄心房颤动患者抗凝治疗依从性的影响
12
作者 王征 闫盈盈 +1 位作者 武东 张帆 《中国循环杂志》 CSCD 北大核心 2024年第9期853-858,共6页
目的:观察共病及衰弱对高龄(≥75岁)心房颤动(房颤)患者抗凝治疗依从性的影响。方法:回顾性选取2016年10月至2019年10月期间于北京大学第三医院老年内科住院的≥75岁非瓣膜性房颤患者528例,其中接受抗凝治疗患者443例(83.9%)。443例患... 目的:观察共病及衰弱对高龄(≥75岁)心房颤动(房颤)患者抗凝治疗依从性的影响。方法:回顾性选取2016年10月至2019年10月期间于北京大学第三医院老年内科住院的≥75岁非瓣膜性房颤患者528例,其中接受抗凝治疗患者443例(83.9%)。443例患者的平均年龄为(84.72±5.39)岁。443例老年房颤患者均接受栓塞风险(CHA_(2)DS_(2)-VASc评分)和出血风险(HAS-BLED、ATRIA评分)评估,并应用衰弱指数量表和年龄校正Charlson共病指数(ACCI)对患者进行评估。衰弱指数≥3分为衰弱,衰弱指数1~2分为衰弱前期;ACCI≥5分为多重共病(高共病负荷)。对出院后接受抗凝治疗的患者进行1年门诊随访,以出院后患者是否停药进行分组比较,观察患者用药依从性并分析其原因。结果:443例老年房颤患者均接受栓塞风险和出血风险评估,CHA_(2)DS_(2)-VASc评分为(5.61±1.57)分,HAS-BLED评分为(3.08±0.89)分,ATRIA评分为(4.13±1.90)分。衰弱指数量表评估显示,所有患者均处于衰弱期或衰弱前期,ACCI平均值为(5.73±1.51)分。随访1年后停用抗凝治疗的患者为96例(21.67%),衰弱(OR=1.114,95%CI:1.041~1.205,P=0.003)、高共病负荷(OR=3.201,95%CI:2.126~4.509,P=0.001)及ATRIA评分定义的高出血风险(ATRIA评分≥5分,OR=1.457,95%CI:1.212~2.075,P=0.024)是用药依从性的影响因素。如果仅观察非死亡所致停药原因,HAS-BLED评分定义的高出血风险(HAS-BLED评分≥3分,OR=1.098,95%CI:1.035~1.116,P=0.014)和应用华法林(OR=1.015,95%CI:1.001~1.030,P=0.040)也是用药依从性的影响因素。结论:高龄(≥75岁)房颤患者出院后抗凝治疗的依从性受衰弱、高共病负荷和ATRIA评分定义的高出血风险评分的影响较为明显。若除外死亡事件,HAS-BLED评分定义的高出血风险和应用华法林也是患者停止抗凝治疗的影响因素。 展开更多
关键词 非瓣膜性心房颤动 抗凝治疗 衰弱 共病指数 用药依从性
下载PDF
数字医疗背景下心房颤动射频消融术后患者拒绝运动康复原因的质性研究
13
作者 汤志杰 孙国珍 +5 位作者 高敏 王洁 鲍志鹏 杨刚 王琳 王琴 《中国全科医学》 CAS 北大核心 2024年第18期2218-2224,共7页
背景基于数字医疗的远程运动康复可高效改善心房颤动射频消融术后患者的健康状况,然而,当前远程运动康复的参与率较低。目的基于休闲限制理论,剖析数字医疗背景下心房颤动射频消融术后患者拒绝运动康复的原因。方法采用目的抽样法,选取2... 背景基于数字医疗的远程运动康复可高效改善心房颤动射频消融术后患者的健康状况,然而,当前远程运动康复的参与率较低。目的基于休闲限制理论,剖析数字医疗背景下心房颤动射频消融术后患者拒绝运动康复的原因。方法采用目的抽样法,选取2022年7—9月在南京医科大学第一附属医院心内科住院或门诊行心房颤动射频消融术后的患者作为研究对象。采取现象学方法,通过半结构式访谈收集拒绝远程运动康复的心房颤动射频消融术后患者资料,采用Colaizzi分析归纳原因。结果本研究最终纳入14例患者。提炼出自身限制因素、人际限制因素和结构限制因素3个主题及下属12个亚主题,即数字素养水平低下、负面疾病感知、疾病所致心理痛苦、数字医疗信任危机、个人运动习惯根深蒂固、康复团队疏离感、社交网络未充分建立、购置设备相关经济负担、恶劣气候、基层康复服务能力不足、角色压力制约可支配时间、可穿戴设备适用性欠佳。结论患者缺乏数字医疗的素养及信任感、高水平疾病感知及心理痛苦、不佳运动习惯、康复团队及同伴间疏远、经济负担、恶劣气候、基层康复服务能力及个人时间匮乏,现有可穿戴设备适用性不足是其拒绝远程运动康复的原因。 展开更多
关键词 心房颤动 运动疗法 康复训练 动机性访谈 数字医疗
下载PDF
心房颤动治疗的基石——口服抗凝药物的研究进展
14
作者 徐艳莉 田艳丰 梁兆光 《心血管康复医学杂志》 CAS 2024年第3期337-340,共4页
心房颤动(房颤)是临床上最常见的心律失常之一,约占所有住院心律失常患者的1/3。随着房颤发病率的升高及人口老龄化的加重,房颤的发病人数将会逐年上升。长期的房颤可引起卒中、心力衰竭等一系列不良临床后果,其中卒中是房颤致死致残的... 心房颤动(房颤)是临床上最常见的心律失常之一,约占所有住院心律失常患者的1/3。随着房颤发病率的升高及人口老龄化的加重,房颤的发病人数将会逐年上升。长期的房颤可引起卒中、心力衰竭等一系列不良临床后果,其中卒中是房颤致死致残的最重要原因,而脑卒中则是其最常见的表现形式,故通过抗凝治疗来预防房颤患者出现卒中便成为房颤治疗的核心策略。而在我国目前有相当一部分房颤患者未接受有效的抗凝治疗,这严重影响了房颤患者的预后和正常生活。目前的抗凝药种类繁多,本文就抗凝药物的研究进展进行综述。 展开更多
关键词 心房颤动 抗凝药 治疗
下载PDF
北京房山区心房颤动脑卒中高危老年人群抗凝治疗调查
15
作者 马云峰 孟庆伟 +2 位作者 韩文芹 伊丽瑾 王朝斌 《脑与神经疾病杂志》 CAS 2024年第5期297-301,共5页
目的通过调查北京市房山区心房颤动(AF)脑卒中高危老年人群的抗凝治疗现状及原因分析,为AF脑卒中高危老年人群规范化的抗凝治疗提供临床依据。方法通过社区体检筛选AF脑卒中65岁及以上高危人群,调查问卷发现AF脑卒中高危人群的抗凝治疗... 目的通过调查北京市房山区心房颤动(AF)脑卒中高危老年人群的抗凝治疗现状及原因分析,为AF脑卒中高危老年人群规范化的抗凝治疗提供临床依据。方法通过社区体检筛选AF脑卒中65岁及以上高危人群,调查问卷发现AF脑卒中高危人群的抗凝治疗现状:结果(1)筛选出符合纳入标准且不存在排除标准AF患者共703例,其中299例(42.5%)患者接受了抗凝治疗,华法林145例,利伐沙班86例,达比加群68例。65~74岁、75~90岁、>90岁3个不同年龄段年龄越大抗凝比例越低,差异有统计学意义(P<0.05);(2)在703例AF患者中267例患脑梗死,其中抗凝109例(40.8%)。无脑梗死患者436例,抗凝为191例(43.8%)。脑梗死组与无脑梗死组抗凝比例差异无统计学意义,P=0.48;(3)AF脑卒中高危人群未抗凝原因有:医生未明确告知需要抗凝(48.5%);患者不知道抗凝的重要性(30.9%);医生明确告知需要抗凝,但患者担心出血(24.8%);虽医生告知需要抗凝,因华法林需要定期检测凝血,医疗条件不允许(21.3%);口服新型抗凝药价格昂贵,负担不起费用(7.9%);(4)年龄、脑梗死、高血压、糖尿病及冠心病作为AF脑卒中高危人群抗凝治疗的影响因素比较差异有统计学意义(P<0.05):结论(1)年龄、脑梗死、高血压、糖尿病及冠心病是AF脑卒中高危人群抗凝治疗的影响因素,年龄越大抗凝比例越低,已经发生脑梗死的患者在诊治过程中并未因心源性脑栓塞抗凝比例增加;(2)AF脑卒中高危人群未抗凝原因中医生未明确告知需要抗凝占比最大,所以需要临床一线医生提高规范诊疗意识,应抗凝则抗,降低AF心源性脑卒中的发生风险。 展开更多
关键词 心房颤动 脑卒中 抗凝治疗
下载PDF
利伐沙班用于HASBLED评分≥3分的高龄非瓣膜性心房颤动患者的有效性和安全性
16
作者 王奕涵 秦旭雁 +5 位作者 韩宣泽 王樱洁 高菲菲 陈春红 张岭楠 张芳 《临床荟萃》 CAS 2024年第2期121-124,共4页
目的前瞻性探讨高龄HASBLED≥3分的非瓣膜性心房颤动(atrial fibrillation,AF)患者应用利伐沙班抗凝治疗的有效性和安全性。方法收集2023年2-9月住院的75岁以上使用利伐沙班抗凝治疗的非瓣膜性AF患者(HASBLED评分≥3分)90例,分为低剂量... 目的前瞻性探讨高龄HASBLED≥3分的非瓣膜性心房颤动(atrial fibrillation,AF)患者应用利伐沙班抗凝治疗的有效性和安全性。方法收集2023年2-9月住院的75岁以上使用利伐沙班抗凝治疗的非瓣膜性AF患者(HASBLED评分≥3分)90例,分为低剂量组(10 mg/d),常规剂量组(15 mg/d)。随访6个月,有效终点事件:缺血性脑卒中、外周动脉栓塞,安全终点事件:大出血和临床有意义的小出血,小出血包括皮下淤血、牙龈出血、血尿、便潜血阳性、眼结膜出血。结果①低剂量组CHA2DS2-VASc评分和HASBLED评分均高于常规剂量组,差异有统计学意义(P<0.05)。②两组治疗前凝血指标比较差异无统计学意义(P>0.05)。③随访6个月,两组均未见到新发缺血性脑卒中、外周栓塞事件。常规剂量组便潜血阳性3例,牙龈出血2例,皮下瘀斑3例。结论高龄HASBLED≥3分的非瓣膜性AF患者应用低剂量利伐沙班抗凝治疗有效、安全。 展开更多
关键词 心房颤动 高龄 HASBLED评分 利伐沙班 抗凝治疗
下载PDF
综合护理干预对心房颤动患者脑梗死发生率的影响
17
作者 柴海霞 李岩 +2 位作者 王珍珍 荆志敏 杨雪娜 《中国实用神经疾病杂志》 2024年第7期897-900,共4页
目的实施综合护理干预并探究其对心房颤动患者脑梗死发生率的影响。方法选取2022-01-2022-12在郑州大学第二附属医院就诊的100例心房颤动患者为研究对象,随机分为对照组和观察组各50例。对照组接受常规护理,观察组在常规护理基础上实施... 目的实施综合护理干预并探究其对心房颤动患者脑梗死发生率的影响。方法选取2022-01-2022-12在郑州大学第二附属医院就诊的100例心房颤动患者为研究对象,随机分为对照组和观察组各50例。对照组接受常规护理,观察组在常规护理基础上实施综合护理干预。比较2组患者6个月、12个月时整体满意度、脑梗死发生率。结果观察组患者整体满意度为(95.36±3.75)分,对照组为(88.24±3.88)分,观察组显著优于对照组(t=8.551,P<0.05)。6个月内观察组脑梗死发生率为2.0%,对照组为4.0%;12个月内观察组脑梗死发生率为3.5%,对照组为6.0%,观察组发生率均较对照组低(P<0.05)。结论综合护理干预策略对提升心房颤动患者的服药依从性作用明显,可增强抗凝治疗效果,进而降低患者脑梗死发生率。 展开更多
关键词 护理干预 心房颤动 依从性 抗凝治疗 脑梗死
下载PDF
县级医院非瓣膜性心房颤动住院患者抗凝治疗影响因素分析
18
作者 叶芸芸 陈治松 宋浩明 《国际心血管病杂志》 2024年第5期312-316,321,共6页
目的:探讨县级医院非瓣膜性心房颤动(NVAF)住院患者抗凝治疗影响因素。方法:回顾性分析广德市人民医院收治的416例NAVF患者的临床资料,根据是否应用口服抗凝药分为抗凝组214例和未抗凝组202例,新型口服抗凝药物(NOAC)治疗的170例患者根... 目的:探讨县级医院非瓣膜性心房颤动(NVAF)住院患者抗凝治疗影响因素。方法:回顾性分析广德市人民医院收治的416例NAVF患者的临床资料,根据是否应用口服抗凝药分为抗凝组214例和未抗凝组202例,新型口服抗凝药物(NOAC)治疗的170例患者根据剂量是否符合欧洲心律协会指南推荐,分为标准剂量组25例与非标准剂量组145例,经单因素和多因素logistic回归分析,筛选出抗凝治疗及NOAC剂量的影响因素。结果:416例NVAF患者中男性245例,平均年龄(76.3±7.6)岁,CHA2DS2-VASc评分为(4.3±1.6)分,HAS-BLED评分为(1.9±0.9)分。多因素logistic回归分析显示,与未抗凝组相比,抗凝组NVAF患者卒中风险高危、收住心内科、合用β受体阻滞剂和肾素-血管紧张素系统(RAS)抑制剂的比例更高(OR=2.87、1.01、1.83、1.80、3.27,P均<0.05)。与标准剂量组相比,非标准剂量组患者年龄≥75岁、肾小球滤过率降低的比例更高(OR=0.08、0.97、P均<0.05)。结论:县级医院NVAF患者的抗凝治疗明显不足,卒中风险高危、收住心内科、合并应用β受体阻滞剂和RAS抑制剂是提高抗凝治疗率的有利因素。年龄大于75岁、肾功能减低是使用NOAC非标准剂量的独立影响因素。 展开更多
关键词 非瓣膜性心房颤动 抗凝药物 标准剂量
下载PDF
1例TAVI术后突发卒中患者抗栓治疗分析
19
作者 高年婷 张锋忠 +1 位作者 李波霞 陈万强 《海峡药学》 2024年第2期68-71,共4页
目的分析讨论房颤合并TAVI术后脑卒中抗栓治疗策略。方法临床药师参与1例67岁男性主动脉瓣重度狭窄合并持续性心房颤动患者TAVI术后突发急性缺血性脑卒中,经充分评估患者卒中分型(NIHSS评分4分)及出血风险(HAS-BLED评分3分)后制定抗栓方... 目的分析讨论房颤合并TAVI术后脑卒中抗栓治疗策略。方法临床药师参与1例67岁男性主动脉瓣重度狭窄合并持续性心房颤动患者TAVI术后突发急性缺血性脑卒中,经充分评估患者卒中分型(NIHSS评分4分)及出血风险(HAS-BLED评分3分)后制定抗栓方案,停用DAPT,换用利伐沙班(20 mg,po,qd)长期抗凝治疗。结果临床药师通过查阅文献及循证证据,结合患者临床情况,对抗栓治疗策略及药物的选择提出建议,患者病情得到有效控制,未再发缺血相关症状,无出血倾向,服药依从性良好。结论临床药师在开展工作期间,应熟练掌握抗栓药物特点,以及不同情况下抗栓治疗策略,结合患者个体情况协助医师制定个体化治疗方案,进一步提高临床药物治疗的有效性和安全性。 展开更多
关键词 心房颤动 TAVI 急性缺血性脑卒中 抗栓治疗
下载PDF
对比仿制与原研达比加群酯胶囊用于非瓣膜性心房颤动患者抗凝治疗临床有效性与安全性评价
20
作者 李华麟 庞婕 +1 位作者 赵云峰 尚振海 《实用药物与临床》 CAS 2024年第6期414-418,共5页
目的评估仿制与原研达比加群酯胶囊的有效性和安全性。方法采用回顾性队列研究,筛选并纳入2021年6月至2022年5月在徐州医科大学附属连云港医院心血管内科住院治疗的非瓣膜性心房颤动(Non-valvular atrial fibrillation,NVAF)患者,根据... 目的评估仿制与原研达比加群酯胶囊的有效性和安全性。方法采用回顾性队列研究,筛选并纳入2021年6月至2022年5月在徐州医科大学附属连云港医院心血管内科住院治疗的非瓣膜性心房颤动(Non-valvular atrial fibrillation,NVAF)患者,根据其所用药品来源分为原研药组(104例)和仿制药组(106例)。两组患者分别口服原研达比加群酯胶囊和仿制达比加群酯胶囊,每次110 mg,每天2次。所有患者服药时间≥1年,随访1年,比较2组患者的有效性指标(脑卒中发生率、体循环栓塞发生率、再次入院率)和安全性指标[出血事件、全因死亡率、主要不良心脑血管事件(Major adverse cardiovascular and cerebrovascular events,MACCE)发生率],并采用Logistic回归模型分析轻微出血事件和全因死亡的危险因素。结果2组患者的脑卒中发生率、体循环栓塞发生率、再次入院率、严重出血率、非严重出血率比较,差异无统计学意义(P>0.05);原研药组患者轻微出血率、全因死亡率均低于仿制药组,差异具有统计学意义(P<0.05)。Logisitic回归分析显示,使用仿制药对轻微出血事件的影响具有统计学意义(OR=2.965,95%CI:1.025~8.576,P=0.045);年龄对全因死亡的影响具有统计学意义(OR=3.330,95%CI:1.060~10.465,P=0.039)。结论与原研药物相比,仿制达比加群酯胶囊用于房颤抗凝治疗疗效可靠,但不良反应发生率较高。 展开更多
关键词 达比加群酯胶囊 非瓣膜性心房颤动 抗凝 仿制药 原研药
下载PDF
上一页 1 2 42 下一页 到第
使用帮助 返回顶部